Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Non-alcoholic Fatty Liver Disease 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 197Nivolumab 145Carboplatin 135Specimen Handling 130Magnetic Resonance Spectroscopy 116Cyclophosphamide 111Paclitaxel 107Cisplatin 97Biopsy 97Radiotherapy 89durvalumab 82Dexamethasone 80atezolizumab 74Ipilimumab 63Gemcitabine 61Rituximab 59Doxorubicin 59Lenalidomide 56Docetaxel 56olaparib 53Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 46Oxaliplatin 46Radiosurgery 43venetoclax 42Prednisone 42Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Lisinopril × Clear all
NCT04550481 2026-01-21

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Northwestern University

Phase 2 Active not recruiting
45 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡